Physician profile
Sam Vafadar
NPI 1093152407
$17,116.16
in general payments reported to CMS, 2019-2025
15 companies · $6,686 in 2025
The $6,686 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,680 · 2022: $5,863 · 2023: $2,755 · 2024: $132 · 2025: $6,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,760 · Consulting Fee: $1,980 · Food and Beverage: $1,656 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,760.30 |
| Consulting Fee | $1,980.00 |
| Food and Beverage | $1,656.36 |
| Education | $176.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $6,007.73 | 2025 | |
| G1 Therapeutics, INC. | $3,489.14 | 2022 | |
| Array Biopharma INC | $1,980.00 | 2023 | Braftovi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,297.56 | 2021-2022 | |
| Janssen Biotech, INC. | $1,026.70 | 2021-2025 | Rybrevant |
| Genentech USA, INC. | $629.73 | 2021-2023 | Tecentriq |
| Astrazeneca Pharmaceuticals LP | $567.86 | 2021-2025 | Imfinzi, Datroway |
| Janssen Scientific Affairs, LLC | $523.53 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $417.24 | 2023-2025 | Libtayo |
| Lilly USA, LLC | $354.30 | 2022-2023 | Retevmo |
| Jazz Pharmaceuticals INC. | $243.55 | 2021-2022 | |
| Blueprint Medicines Corporation | $175.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $149.65 | 2022-2025 | Opdivo |
| Daiichi Sankyo INC. | $138.33 | 2025 | Datroway |
| Amgen INC. | $115.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Vafadar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.